集束化治疗对低分级动脉瘤性蛛网膜下腔出血患者临床结局的影响:倾向性评分匹配分析
本研究为采用2008至2022年历史对照的比较研究,集束化治疗于2017年引入。共纳入90例连续低分级(Hunt和Hess分级IV和V级)动脉瘤性蛛网膜下腔出血患者,43例接受集束化治疗,47例接受常规治疗。经1:1倾向性评分匹配后每组31对。集束化治疗组6个月良好功能结局(改良Rankin量表评分0-2分)比例为46.4%,显著高于常规组的20.7%(p=0.04);6个月死亡率集束化治疗组为14.3%,常规组为27.3%(p=0.01)。集束化治疗(OR 14.6,95%CI 2.1-100.0,p<0.01)和初始存在瞳孔反射(OR 12.0,95%CI 1.4-104.6,p=0.02)与6个月良好功能结局显著相关。结论认为集束化治疗改善低分级aSAH患者的6个月功能结局和死亡率。
要点
- 匹配后集束化治疗组6个月良好功能结局(mRS 0-2分)为46.4%,常规组为20.7%(p=0.04)。
- 匹配后集束化治疗组6个月死亡率为14.3%,常规组为27.3%(p=0.01)。
- 集束化治疗与6个月良好功能结局显著相关(OR 14.6,95%CI 2.1-100.0,p<0.01)。
- 初始存在瞳孔反射与6个月良好功能结局显著相关(OR 12.0,95%CI 1.4-104.6,p=0.02)。
- 匹配前集束化治疗组HH V级比例更高(41.9% vs. 27.7%),常规组初始瞳孔固定比例更高(38.3% vs. 30.2%)。
适用人群与场景
- 低分级动脉瘤性蛛网膜下腔出血患者,定义为Hunt和Hess分级IV级和V级。
- 研究纳入2008至2022年共90例连续患者,集束化治疗于2017年引入。
诊断标准与关键阈值
- 低分级动脉瘤性蛛网膜下腔出血定义为Hunt和Hess(HH)分级IV级和V级。
- 良好功能结局定义为6个月时改良Rankin量表(mRS)评分0-2分。
研究设计与关键结果
- 研究类型为采用2008至2022年历史对照的比较研究,集束化治疗于2017年引入,共纳入90例连续患者,43例接受集束化治疗,47例接受常规治疗。
- 匹配前集束化治疗组HH V级比例高于常规组(41.9% vs. 27.7%),常规组初始检查瞳孔固定比例高于集束化治疗组(38.3% vs. 30.2%)。
- 经1:1倾向性评分匹配后每组31对;集束化治疗组6个月良好功能结局比例为46.4%,常规组为20.7%(p=0.04)。
- 匹配后集束化治疗组6个月死亡率为14.3%,常规组为27.3%(p=0.01)。
- 集束化治疗与6个月良好功能结局显著相关(OR 14.6,95%CI 2.1-100.0,p<0.01)。
- 初始存在瞳孔反射与6个月良好功能结局显著相关(OR 12.0,95%CI 1.4-104.6,p=0.02)。
证据类型、等级与局限
- 证据类型:采用历史对照的比较研究,使用倾向性评分匹配方法。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,集束化治疗改善低分级aSAH患者的6个月功能结局和死亡率。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Poor-grade aneurysmal subarachnoid hemorrhage (aSAH), defined as Hunt and Hess (HH) grades IV and V, is a challenging disease because of its high mortality and poor functional outcomes. The effectiveness of bundled treatments has been demonstrated in critical diseases. Therefore, poor-grade aSAH bundled treatments have been established. This study aims to evaluate whether bundled treatments can improve long-term outcomes and mortality in patients with poor-grade aSAH.
METHODS: This is a comparative study using historical control from 2008 to 2022. Bundled treatments were introduced in 2017. We compared the rate of favorable outcomes (modified Rankin Scale score 0-2) at 6 months and mortality before and after the introduction of the bundled treatments. To eliminate confounding bias, the propensity score matching method was used.
RESULTS: A total of 90 consecutive patients were evaluated. Forty-three patients received bundled treatments, and 47 patients received conventional care. The proportion of patients with HH grade V was higher in the bundle treatment group (41.9% vs. 27.7%). Conversely, the proportion of patients with fixed pupils on the initial examination was higher in the conventional group (30.2% vs. 38.3%). After 1:1 propensity score matching, 31 pairs were allocated to each group. The proportion of patients with 6-month favorable functional outcomes was significantly higher in the bundled treatments group (46.4% vs. 20.7%, p = 0.04). The 6-month mortality rate was 14.3% in the bundled treatments group and 27.3% in the conventional group (p = 0.01). Bundled treatments (odd ratio 14.6 [95% confidence interval 2.1-100.0], p < 0.01) and the presence of an initial pupil reflex (odd ratio 12.0 [95% confidence interval 1.4-104.6], p = 0.02) were significantly associated with a 6-month favorable functional outcome.
CONCLUSIONS: The bundled treatments improve 6-month functional outcome and mortality in patients with poor-grade aSAH.
参考来源
- Choi YH, Ha EJ, Shim Y, et al. Clinical Outcome of Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage with Bundled Treatments: A Propensity Score-Matched Analysis. Neurocrit Care. 2023. PMID: 37610642. doi:10.1007/s12028-023-01818-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。